Zydus Cadila has received the tentative approval from the United States Food & Drug Administration (USFDA) to market Lacosamide Tablets (US RLD -Vimpat) in the strengths of 50 mg, 100 mg, 150 mg and 200 mg. Lacosamide is an anticonvulsant or antiepileptic drug, used to prevent and control seizures. It works by reducing the spread of seizure activity in the brain. The drug will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad in the state of Gujarat.
The group now has 261 approvals and has so far filed over 350 ANDA’s since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
